Tuesday, June 2
Health

At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

No Comments2 Mins Read
ASCO News: Bristol and Pfizer report favorable results — Day 1

Adam Feuerstein/STAT

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

Matthew Herper covers medical innovation — both its promise and its perils.

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.

Katherine MacPhail is a reporter and editorial events programmer for STAT.

We asked Brian Wolpin, the presenter for yesterday’s plenary on the daraxonrasib pancreatic cancer study, about the sustained standing ovation that interrupted his remarks.

“Honestly, it was tough to hold it together in that moment and then keep going. It felt like 20 years of work all rolled into 12 minutes,” he told us.

It was a truly memorable ASCO meeting. With this newsletter, we say goodbye from Chicago. Thanks again for spending time with us. You can still join our virtual recap on Wednesday!

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

See also  Deadliest Drug: Key takeaways from our series on alcohol and health

Subscribe

  1. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

  2. Senior Writer, Medicine, Editorial Director of Events

Share.

Related Posts

Add A Comment

Leave A Reply